



## **Atypical Antipsychotics Prior Authorization Request Form (Page 1 of 4)**

**Note:** If the following information is NOT filled in completely, correctly, or legibly the PA process **may** be delayed. **Please complete one form per member.** 

Member Information (required)			Provider Information (required)			
Member Name:			Provider Name:			
Insurance ID#:			NPI#: Specialty:			
Date of Birth:			Office Phone:			
Street Address:			Office Fax:			
City: State: Zip:			Office Street Address:			
Phone:			City:		State:	Zip:
		Medication In	formation (requ	uired)		
Medication Name:			Strength:		Dosage	Form:
☐ Check if requesting <b>brand</b>			Directions for Use:			
☐ Check if request is for <b>cont</b>	inuation of the	гару				
		Clinical Info	rmation (require	ed)		
Is this a tapering off dose for	or discontinuat		` '	·		
Select the diagnosis belo						
☐ Chronic Aggression						
☐ Depressive Episodes of Bipolar Disorder (Bipolar Depression)						
Major Depressive Disord						
Major Depressive Disord						
Manic or Mixed Episode	sorder					
Oppositional Defiant Dis						
Pervasive Developmental Disorder (PDD)/Autism/Irritability associated with Autism/PDD						
☐ Schizophrenia/Schizoaff			of a Discolar			
<ul><li>Suicidal Behavior assoc</li><li>Tics</li></ul>	ciated with Sch	izopnrenia/Schizoaπe	ctive Disorder			
<ul><li>□ Tourette's Disorder</li><li>□ Treatment-Resistant Major Depressive Disorder (MDD)</li></ul>						
☐ Treatment-Resistant Major Depressive Disorder (MDD)						
Other (specify):						
Answer the following:						
Is the member being referre	ed to a psychia	atrist and awaiting an	appointment? 🗖 Y	res □ No		
Date of appointment: Psychiatrist:						
What is the member's age i						
Is there a monitoring plan/w medication?    Yes   No		r be monitored for eva	aluating safety and	effectivene	ess of the	



## Atypical Antipsychotics Prior Authorization Request Form (Page 2 of 4)

Medication	Al Nama)	Under FDA-Approved Age		
Generic Name (Bran	<u> </u>	of years of any far suffer /DDD or Tourstte's 140 years of any far		
Aripiprazole oral solution and oral disintegrating tablets (Abilify/Abilify Discmelt)		<6 years of age for autism/PDD or Tourette's; <10 years of age for bipolar; <13 years of age for schizophrenia; <18 years of age for MDD		
Aripiprazole tablets (Abilify)		<6 years of age for autism/PDD or Tourette's; <10 years of age for other diagnoses		
Aripiprazole long-acting injection (Abilify Maintena, Abilify MyCite, Aristada, Aristada Initio)		<18 years of age		
Brexpiprazole (Rexulti)		<18 years of age		
Cariprazine (Vraylar)		<18 years of age		
Clozapine (Clozaril, FazaClo, Versacloz)		<18 years of age		
Iloperidone (Fanapt)		<18 years of age		
Ziprasidone (Geodon)		<18 years of age		
Paliperidone (Invega)		<12 years of age		
Paliperidone long-acting injection (Invega Sustenna/Trinza)		<18 years of age		
Lurasidone (Latuda)		<10 years of age for bipolar depression; <13 years of age for schizophrenia		
Risperidone (Risperdal/Risperdal M-Tab)		<5 years of age for autism/PDD; <10 years of age for other diagnoses		
Risperidone long-acting injection (Risperdal Consta)		<18 years of age		
Asenapine (Saphris)		<10 years of age for bipolar; <18 years of age for schizophrenia		
Quetiapine immediate-release (Seroquel)		<10 years of age		
Quetiapine extended-release (Seroquel XR)		<10 years of age		
Olanzapine/fluoxetine (Symbyax)		<18 years of age for treatment-resistant MDD; <10 years of age fo bipolar depression		
Olanzapine (Zyprexa/Zyprexa Zydis)		<10 years of age for bipolar depression; <13 years of age for othe diagnoses		
Olanzapine long-acting injection (Zyprexa Relprevv)		<18 years of age		
NOTE: Section A or B MUST be	completed below.			
SECTION A: The member has be	<del>-</del>	quested medication		
low long has the member been taking the	e requested medication?	2 weeks □ ≥ 2 weeks		
las the member shown improvement in s	•			
yes, please check one or more boxes b				
Blunted affect	☐ Hallucinatory beha	vior		
Conceptual disorganization	☐ Hostility			
Delusions	·	ty and flow of conversation		
Depressive symptoms ☐ Passive/apathetic s		social withdrawal		
Difficulty in abstract thinking ☐ Poor rapport				
<b>1</b> Emotional withdrawal ☐ Stereotyped thinkin		ing		
<b>1</b> Excitement □ Suicidal thoughts				
□ Grandiosity □ Suspiciousness/persecution				
1 Other:				



## **Atypical Antipsychotics Prior Authorization Request Form (Page 3 of 4)**

☐ SECTION B: The member has ne	ver taken the requested medication				
Which of the following preferred medic	ations has the member tried? (check a	all that apply)			
☐ Aripiprazole <b>Dates</b> :	☐ Ziprasidone <b>Dates</b> :	Olanzapine <b>Dates</b> :			
☐ Risperidone Dates:					
•	•	er. (complete for each applicable drug in the			
Drug	Reason inappropriate ch	poice for member			
Aripiprazole					
Latuda					
Olanzapine					
Risperidone					
Quetiapine IR/ER					
Ziprasidone					
	extended-release and olanzapine-flus not adequate for the member. (compl	uoxetine for major depressive disorder only: lete for each drug/class)			
Drug		e, response, and dates of therapy			
SNRIs (desvenlafaxine [Pristiq], duloxetine [Cymbalta], venlafaxine [Effexor/XR])	List medication hame	, response, and dates of therapy			
SSRIs (citalopram [Celexa],					
escitalopram [Lexapro], fluvoxamine [Luvox], fluoxetine [Prozac],					
paroxetine [Paxil], or sertraline					
[Zoloft])					
Other Antidepressants (bupropion,					
mirtazapine, trazodone, vortioxetine;					
list may not be all inclusive)					
,					
☐ SECTION C. If an orally disintegr following:	ating dosage formulation or oral sol	ution is being requested, also answer the			
What prevents the member from taking the	regular oral dosage form? (check all that a	(ylqqı			
☐ Dysphagia ☐ Compliance monit		nined from solid oral dosage form			
☐ Other (specify):	<b>.</b>	Ü			
	ristada/Aristada Initio, Invega Suste	enna, Invega Trinza, Risperdal Consta or			
Has the member tried oral aripiprazole (if Abilify Maintena or Aristada/Aristada Initio is being requested), oral risperidone or oral paliperidone (if Risperdal Consta or Invega Sustenna is being requested), Invega Sustenna (if Invega Trinza is being requested) or oral olanzapine (if Zyprexa Relprevv is being requested) or does the member have a history of noncompliance with oral medications and is unable to receive a trial of the appropriate oral atypical antipsychotic before starting long-acting therapy with injection or is the member unable to swallow or use orally disintegrating tablets?   Yes Date of last therapy:  No					
Is the prescribing physician a psychiatrist of	r has a psychiatrist been consulted?   Ye	es 🗆 No			
Where will the medication be administered?					
		ional			
<ul> <li>Home health or other outpatient pharmacy setting by a trained health care professional</li> <li>Long-term care facility</li> </ul>					
-					
☐ CSB (Community Service Board)					
☐ Physician office or clinic**					
Other (specify):	<del></del>				
		nic other than a CSB, please go to the Registered User ortal to request a PA from Physician Services.			

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: AtypicalAntipsychotics\_GAM\_2020January



## **Atypical Antipsychotics Prior Authorization Request Form (Page 4 of 4)**

SECTION E: In the space below, please provide lest clinically relevant in evaluating the prior authorization.	tter of medical necessity and any additional information you deem
Physician signature	
Physician signature: Contact person:	
re there any other comments, diagnoses, symptoms, medication view?	ns tried or failed, and/or any other information the physician feels is important to this
<u>lease note</u> : This request may be denied unless all required i For urgent or expedited requests please call 1-8	ntormation is received. 66-525-5827.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose P

This form may be used for non-urgent requests and faxed to 1-888-491-9742.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: AtypicalAntipsychotics\_GAM\_2020January